Sugi Predict

Sugi Predict / Targets / PIK3R1

PIK3R1

Phosphatidylinositol 3-kinase regulatory subunit alpha · P27986 · PIK3R1 on Sugi Atlas →

110,921 patent compounds predicted against PIK3R1, 71,526 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9190 SCHEMBL9190 1.00 7/20
SCHEMBL9272 SCHEMBL9272 1.00 7/20
SCHEMBL9623 SCHEMBL9623 1.00 7/20
SCHEMBL14698 SCHEMBL14698 1.00 7/20
SCHEMBL11162 SCHEMBL11162 0.99 7/20
SCHEMBL11744 SCHEMBL11744 0.90 7/20
SCHEMBL11320 SCHEMBL11320 0.90 7/20
SCHEMBL8616 SCHEMBL8616 0.89 7/20
SCHEMBL10985 SCHEMBL10985 0.87 7/20
SCHEMBL9212 SCHEMBL9212 0.87 7/20
SCHEMBL11538 SCHEMBL11538 0.86 7/20
SCHEMBL11350 SCHEMBL11350 0.86 7/20
SCHEMBL11166 SCHEMBL11166 0.86 7/20
SCHEMBL9343 SCHEMBL9343 0.86 7/20
SCHEMBL11402 SCHEMBL11402 0.85 7/20
SCHEMBL11377 SCHEMBL11377 0.85 7/20
SCHEMBL11376 SCHEMBL11376 0.84 7/20
SCHEMBL11503 SCHEMBL11503 0.84 7/20
SCHEMBL14749 SCHEMBL14749 0.83 7/20
SCHEMBL11146 SCHEMBL11146 0.83 7/20

Clinical trials — most relevant to PIK3R1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adjuvant Low Dose Aspirin in Colorectal Cancer PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations PHASE3COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia PHASE2WITHDRAWN
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PHASE2ACTIVE_NOT_RECRUITING
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss PHASE2RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
PIK3CA in HER2+ BC and pCR Trial nanUNKNOWN
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive? nanUNKNOWN
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3R1 binder may also engage these)

ProteinNameSimilarity
Q63787 — 1.000 Q63787 →
Q5R685 — 1.000 Q5R685 →
P26450 — 1.000 P26450 →
P23727 — 1.000 P23727 →
Q8UUU2 — 0.990 Q8UUU2 →
Q7YQL6 — 0.981 Q7YQL6 →
O60890 — 0.979 O60890 →
Q6ZQ82 — 0.976 Q6ZQ82 →
Q7YQL5 — 0.976 Q7YQL5 →
Q08DP6 — 0.975 Q08DP6 →
Q5ZMW5 — 0.973 Q5ZMW5 →
Q6Y5D8 — 0.973 Q6Y5D8 →
B5DFQ4 — 0.972 B5DFQ4 →
Q9UNA1 — 0.972 Q9UNA1 →
P0CAX5 — 0.972 P0CAX5 →
Q8AVG0 — 0.972 Q8AVG0 →
A6NI28 — 0.972 A6NI28 →
Q99J31 — 0.971 Q99J31 →
A1A4S6 — 0.971 A1A4S6 →
Q5U4T3 — 0.970 Q5U4T3 →
A4II46 — 0.970 A4II46 →
Q62696 — 0.970 Q62696 →
O60879 — 0.968 O60879 →
Q08CW1 — 0.967 Q08CW1 →
O46404 — 0.967 O46404 →
Q80TY0 — 0.967 Q80TY0 →
USO1 General vesicular transport factor p115 0.967 landscape →
Q63789 — 0.966 Q63789 →
P41541 — 0.966 P41541 →
PRKD1 Serine/threonine-protein kinase D1 0.966 landscape →